We use cookies for a better user experience. Read our Privacy Policy
I Agree
Hemostatic Agents Market
Hemostatic Agents Market - Snapshot
The global hemostatic agents market is expanding due to increasing number of surgical procedures across the globe. The global hemostatic agents market was valued at more than US$ 2.8 Bn in 2015. It is expected to expand at a compound annual growth rate (CAGR) of over 6.0% from 2018 to 2022 to reach the value of US$ 4.1 Bn by 2022. The global market is expanding at a relatively higher growth rate owing to an increase in the geriatric population, adoption of hemostatic products to curb bleeding, and rise in research and development in both developed and developing markets.
Hemostasis is a process that involves stoppage of bleeding or blood flow through a blood vessel, or hemorrhage. In hemostasis, a clot is formed at the injured area, thereby repairing the blood vessel. Hemostasis consists of primary hemostasis, secondary hemostasis, and fibrinolysis. In case of a blood vessel injury, platelets combine together to form a plug. An interaction of proteins occurs, known as clotting factors, for the formation of a fibrin mesh to hold the platelets in place. This results in the healing of the injury, while preventing blood from escaping the blood vessel. Hemostatic agents are utilized to stem blood flow via the increased promotion of clotting, thereby improving the hemostasis by accelerating the coagulation process. These agents enhance hemostasis by progressing primary hemostasis, increasing fibrin formation, or inhibiting fibrinolysis. Hemostatic agents play a vital role in the treatment or prevention of bleeding, thereby indicating their usage in various therapeutic areas. According to a study by U.S. Army Institute of Surgical Research (USAISR), the survivability rate drops to just 14% if blood loss continues and the patient goes into Stage II shock or greater.
The global hemostatic agents market has been broadly segmented based on product type, specialty / therapeutic area, size of hospitals, and region. In terms of product type, the market has been classified into active, passive, and combination products. Active agents are expected to hold a significant share of the market and are differentiated from passive hemostats by their thrombin content and due to their improved efficacy, thrombin-based hemostats, i.e. active agents, is projected to expand at a significant CAGR during the forecast period. Passive agents, also called mechanical agents, are not often used in procedures, such as spinal surgeries, in which active agents and combinations are preferred. In certain cases, passive hemostat’s “stickiness” to both instruments and tissues is an additional hindrance to its use. Therefore, the passive segment of the market is estimated to expand at a CAGR 3.43% during the forecast period. However, since they are the oldest hemostatic agents they, currently, hold a considerable market share.
In terms of specialty / therapeutic area, the global hemostatic agents market has been segregated into cardiology, cath lab, trauma, general surgery, OB/GYN, transplant, oncology, neurology, orthopedic, plastic surgery, dental, and others (urological surgeries, pulmonary surgeries). General surgery, cardiology, and trauma segments are expected to hold a major share of the market during the forecast period due to the increase in number of cases in these therapeutic areas. In 2015, according to CDC, in the U.S., approximately 610,000 people die due to heart disease, every year, accounting 1 in every 4 deaths, and coronary heart disease (CHD) is considered to be the most common type of heart disease, causing the death of 370,000 people per year.
In terms of size of hospitals, the global hemostatic agents market has been divided into large hospitals (500+ bed size), medium hospital (250-499 beds), and small hospitals (less than 250 beds). Large hospitals and medium hospitals segments are expected to maintain their dominance and gain market share by the end of the forecast period. Availability of well-equipped infrastructure, facilities, resources, high surgery volume, and medical professionals & care has led to their prominent share in the global market. Partnerships and network by prominent hospitals with key players in the hemostatic agents market, is also the reason for their increased market share.
In terms of region, the global hemostatic agents market has been segmented into North America, Europe, Asia Pacific, South Africa, and RoW. North America dominated the global market and is expected to maintain its dominance by the end of 2022. The market in North America is predominantly driven by rapid increase in geriatric population, rise in number of surgical procedures, and increase in patient population. Moreover, increasing number of players and products, coupled with sturdy focus on research and development, is a key factor driving the market in the U.S. The market in Asia Pacific is projected to expand at a prominent CAGR during the forecast period. Increasing population, initiatives taken by governments in healthcare, and rise in research and development activities are key factors driving the market in Asia Pacific.
Companies such as Baxter, Ethicon US, LLC., Pfizer Inc., and C. R. Bard, Inc. accounted for a major share of the global market in 2015. Strong network with hospitals and distributors, effective and wide product lines, and extensive involvement in research and development, are key factors boosting the position of these players in the market. In January 2018, Ethicon US, LLC., launched a powdered adjunctive hemostat, called Surgicel powder absorbable hemostat. It is utilized to help surgeons efficiently and effectively control disruptive bleeding. In March 2018, Baxter completed the acquisition of RECOTHROM and PREVELEAK, thus broadening its surgical hemostat and sealant portfolio. Companies are focused on strategic collaborations and acquisitions with parallel companies to strengthen their presence in the global market.
The global hemostatic agents market has been segmented as mentioned below:
|
by Product Type |
|
|
by Specialty / Therapeutic Area |
|
|
by Size of Hospitals |
|
|
by Region |
|
1. Research Intent and Scope of the Study
2. Assumptions and Research Methodology
3. Market Overview
4. Premium Insights
4.1. Overall Pricing Assessment
4.1.1. Trends in Pricing of Hemostatic Agents (Overall Level), 2015?2022
4.2. Country Level Pricing Assessment (Key Countries)
4.2.1. U.S.
4.2.2. Canada
4.2.3. Germany
4.2.4. France
4.2.5. U.K.
4.2.6. Spain
4.2.7. Italy
4.2.8. China
4.2.9. India
4.2.10. Australia
4.2.11. Japan
4.2.12. South Korea
4.2.13. South Africa
4.3. Regulatory & Reimbursement Assessment (Key Countries)
4.3.1. U.S.
4.3.2. Canada
4.3.3. Germany
4.3.4. France
4.3.5. U.K.
4.3.6. Spain
4.3.7. Italy
4.3.8. China
4.3.9. India
4.3.10. Australia
4.3.11. Japan
4.3.12. South Korea
4.3.13. South Africa
4.4. Comparative Assessment of Key Products
4.5. Key Distributors (Key Countries)
4.5.1. U.S.
4.5.2. Canada
4.5.3. Germany
4.5.4. France
4.5.5. U.K.
4.5.6. Spain
4.5.7. Italy
4.5.8. China
4.5.9. India
4.5.10. Australia
4.5.11. Japan
4.5.12. South Korea
4.5.13. South Africa
5. North America Hemostatic Agents Market
5.1. U.S. Hemostatic Agents Market
5.1.1. U.S. Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
5.1.1.1. Active Agents
5.1.1.2 Passive Agents
5.1.1.3 Combination
5.1.2. U.S. Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
5.1.2.1. Cardiology
5.1.2.2. Cath Lab
5.1.2.3. Trauma
5.1.2.4. General Surgery
5.1.2.5. ObGyn
5.1.2.6. Transplant
5.1.2.7. Oncology
5.1.2.8. Neurology
5.1.2.9. Orthopedic
5.1.2.10. Plastic Surgery
5.1.2.11. Dental
5.1.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
5.1.3. U.S. Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
5.1.3.1. Large Hospitals (500+ bed size)
5.1.3.2. Medium Hospital (250-399 beds)
5.1.3.3. Small Hospitals (less than 250 beds)
5.1.4. Competition Landscape Assessment – U.S. Hemostatic Agents Market
5.1.5. Brand Assessment: Most Popular Hemostatic Brands-U.S.
5.1.6. Winning Imperatives - Decision Making Criteria-U.S.
5.1.7. Strategic Developments (Hemostatic Agents) – U.S.
5.1.8. Criss-cross Assessment – Product Vs Specialty –U.S.
5.1.9. Market Drivers, Restraints, Opportunities, and Trends – U.S
5.1.10. Decision-making Process - U.S.
5.1.10.1. Purchase Decision-making Process- U.S.
5.1.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- U.S.
5.1.10.3. Selection Criteria for Distributors- U.S.
5.1.11. Sales Channel Assessment – U.S. Hemostatic Agents Market
5.1.12. Customer Landscape
5.1.12.1. Concentration of Hospitals in U.S. – Heat Map & Detailed Hospital Segmentation, by Bed Size
5.1.12.2. Key Users of Products, by Specialty/Therapeutic Area – U.S.
5.2. Canada Hemostatic Agents Market
5.2.1. Canada Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
5.2.1.1. Active Agents
5.2.1.2 Passive Agents
5.2.1.3 Combination
5.2.2. Canada Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
5.2.2.1. Cardiology
5.2.2.2. Cath Lab
5.2.2.3. Trauma
5.2.2.4. General Surgery
5.2.2.5. ObGyn
5.2.2.6. Transplant
5.2.2.7. Oncology
5.2.2.8. Neurology
5.2.2.9. Orthopedic
5.2.2.10. Plastic Surgery
5.2.2.11. Dental
5.2.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
5.2.3. Canada Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
5.2.3.1. Large Hospitals (500+ bed size)
5.2.3.2. Medium Hospital (250-499 beds)
5.2.3.3. Small Hospitals (less than 250 beds)
5.2.4. Competition Landscape Assessment – Canada Hemostatic Agents Market
5.2.5. Brand Assessment: Most Popular Hemostatic Brands-Canada
5.2.6. Winning Imperatives - Decision Making Criteria-Canada
5.2.7. Strategic Developments (Hemostatic Agents) – Canada
5.2.8. Criss-cross Assessment – Product vs. Specialty –Canada
5.2.9. Market Drivers, Restraints, Opportunities, and Trends – Canada
5.2.10. Decision-making Process - Canada
5.2.10.1. Purchase Decision-making Process - Canada
5.2.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- Canada
5.2.10.3. Selection Criteria for Distributors - Canada
5.2.11. Sales Channel Assessment – Canada Hemostatic Agents Market
5.2.12. Customer Landscape
5.2.12.1. Concentration of Hospitals in Canada – Heat Map & Detailed Hospital Segmentation, by Bed Size
5.2.12.2. Key Users of Products, by Specialty/Therapeutic Area – Canada
6. Europe Hemostatic Agents Market
6.1. Germany Hemostatic Agents Market
6.1.1. Germany Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
6.1.1.1. Active Agents
6.1.1.2 Passive Agents
6.1.1.3 Combination
6.1.2. Germany Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
6.1.2.1. Cardiology
6.1.2.2. Cath Lab
6.1.2.3. Trauma
6.1.2.4. General Surgery
6.1.2.5. ObGyn
6.1.2.6. Transplant
6.1.2.7. Oncology
6.1.2.8. Neurology
6.1.2.9. Orthopedic
6.1.2.10. Plastic Surgery
6.1.2.11. Dental
6.1.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
6.1.3. Germany Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
6.1.3.1. Large Hospitals (500+ bed size)
6.1.3.2. Medium Hospital (250-499 beds)
6.1.3.3. Small Hospitals (less than 250 beds)
6.1.4. Competition Landscape Assessment – Germany Hemostatic Agents Market
6.1.5. Brand Assessment: Most Popular Hemostatic Brands-Germany
6.1.6. Winning Imperatives - Decision Making Criteria - Germany
6.1.7. Strategic Developments (Hemostatic Agents) – Germany
6.1.8. Criss-cross Assessment – Product vs. Specialty – Germany
6.1.9. Market Drivers, Restraints, Opportunities, and Trends – Germany
6.1.10. Decision-making Process - Germany
6.1.10.1. Purchase Decision-making Process - Germany
6.1.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- Germany
6.1.10.3. Selection Criteria for Distributors- Germany
6.1.11. Sales Channel Assessment – Germany Hemostatic Agents Market
6.1.12. Customer Landscape
6.1.12.1. Concentration of Hospitals in Germany – Heat Map & Detailed Hospital Segmentation, by Bed Size
6.1.12.2. Key Users of Products, by Specialty/Therapeutic Area – Germany
6.2. France Hemostatic Agents Market
6.2.1. France Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
6.2.1.1. Active Agents
6.2.1.2 Passive Agents
6.2.1.3 Combination
6.2.2. France Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
6.2.2.1. Cardiology
6.2.2.2. Cath Lab
6.2.2.3. Trauma
6.2.2.4. General Surgery
6.2.2.5. ObGyn
6.2.2.6. Transplant
6.2.2.7. Oncology
6.2.2.8. Neurology
6.2.2.9. Orthopedic
6.2.2.10. Plastic Surgery
6.2.2.11. Dental
6.2.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
6.2.3. France Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
6.2.3.1. Large Hospitals (500+ bed size)
6.2.3.2. Medium Hospital (250-499 beds)
6.2.3.3. Small Hospitals (less than 250 beds)
6.2.4. Competition Landscape Assessment – France Hemostatic Agents Market
6.2.5. Brand Assessment: Most Popular Hemostatic Brands - France
6.2.6. Winning Imperatives - Decision Making Criteria-France
6.2.7. Strategic Developments (Hemostatic Agents) – France
6.2.8. Criss-cross Assessment – Product vs. Specialty – France
6.2.9. Market Drivers, Restraints, Opportunities, and Trends – France
6.2.10. Decision-making Process - France
6.2.10.1. Purchase Decision-making Process - France
6.2.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- France
6.2.10.3. Selection Criteria for Distributors - France
6.2.11. Sales Channel Assessment – France Hemostatic Agents Market
6.2.12. Customer Landscape
6.2.12.1. Concentration of Hospitals in France – Heat Map & Detailed Hospital Segmentation, by Bed Size
6.2.12.2. Key Users of Products, by Specialty/Therapeutic Area – France
6.3. U.K. Hemostatic Agents Market
6.3.1. U.K. Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
6.3.1.1. Active Agents
6.3.1.2. Passive Agents
6.3.1.3 Combination
6.3.2. U.K. Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
6.3.2.1. Cardiology
6.3.2.2. Cath Lab
6.3.2.3. Trauma
6.3.2.4. General Surgery
6.3.2.5. ObGyn
6.3.2.6. Transplant
6.3.2.7. Oncology
6.3.2.8. Neurology
6.3.2.9. Orthopedic
6.3.2.10. Plastic Surgery
6.3.2.11. Dental
6.3.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
6.3.3. U.K. Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
6.3.3.1. Large Hospitals (500+ bed size)
6.3.3.2. Medium Hospital (250-399 beds)
6.3.3.3. Small Hospitals (less than 250 beds)
6.3.4. Competition Landscape Assessment – U.K. Hemostatic Agents Market
6.3.5. Brand Assessment: Most Popular Hemostatic Brands-U.K.
6.3.6. Winning Imperatives - Decision Making Criteria - U.K.
6.3.7. Strategic Developments (Hemostatic Agents) – U.K.
6.3.8. Criss-cross Assessment – Product vs. Specialty –U.K.
6.3.9. Market Drivers, Restraints, Opportunities, and Trends – U.K.
6.3.10. Decision-making Process- U.K.
6.3.10.1. Purchase Decision-making Process - U.K.
6.3.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - U.K.
6.3.10.3. Selection Criteria for Distributors - U.K.
6.3.11. Sales Channel Assessment – U.K. Hemostatic Agents Market
6.3.12. Customer Landscape
6.3.12.1. Concentration of Hospitals in U.K. – Heat Map & Detailed Hospital Segmentation, by Bed Size
6.3.12.2. Key Users of Products, by Specialty/Therapeutic Area – U.K.
6.4. Spain Hemostatic Agents Market
6.4.1. Spain Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
6.4.1.1. Active Agents
6.4.1.2. Passive Agents
6.4.1.3 Combination
6.4.2. Spain Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
6.4.2.1. Cardiology
6.4.2.2. Cath Lab
6.4.2.3. Trauma
6.4.2.4. General Surgery
6.4.2.5. ObGyn
6.4.2.6. Transplant
6.4.2.7. Oncology
6.4.2.8. Neurology
6.4.2.9. Orthopedic
6.4.2.10. Plastic Surgery
6.4.2.11. Dental
6.4.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
6.4.3. Spain Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
6.4.3.1. Large Hospitals (500+ bed size)
6.4.3.2. Medium Hospital (250-499 beds)
6.4.3.3. Small Hospitals (less than 250 beds)
6.4.4. Competition Landscape Assessment – Spain Hemostatic Agents Market
6.4.5. Brand Assessment: Most Popular Hemostatic Brands-Spain
6.4.6. Winning Imperatives - Decision Making Criteria - Spain
6.4.7. Strategic Developments (Hemostatic Agents) – Spain
6.4.8. Criss-cross Assessment – Product vs. Specialty –Spain
6.4.9. Market Drivers, Restraints, Opportunities, and Trends – U.K.
6.4.10. Decision-making Process - Spain
6.4.10.1. Purchase Decision-making Process - Spain
6.4.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - Spain
6.4.10.3. Selection Criteria for Distributors - Spain
6.4.11. Sales Channel Assessment – Spain Hemostatic Agents Market
6.4.12. Customer Landscape
6.4.12.1. Concentration of Hospitals in Spain – Heat Map & Detailed Hospital Segmentation, by Bed Size
6.4.12.2. Key Users of Products, by Specialty/Therapeutic Area – Spain
6.5. Italy Hemostatic Agents Market
6.5.1. Italy Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
6.5.1.1. Active Agents
6.5.1.2 Passive Agents
6.5.1.3 Combination
6.5.2. Italy Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
6.5.2.1. Cardiology
6.5.2.2. Cath Lab
6.5.2.3. Trauma
6.5.2.4. General Surgery
6.5.2.5. ObGyn
6.5.2.6. Transplant
6.5.2.7. Oncology
6.5.2.8. Neurology
6.5.2.9. Orthopedic
6.5.2.10. Plastic Surgery
6.5.2.11. Dental
6.5.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
6.5.3. Italy Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
6.5.3.1. Large Hospitals (500+ bed size)
6.5.3.2. Medium Hospital (250-499 beds)
6.5.3.3. Small Hospitals (less than 250 beds)
6.5.4. Competition Landscape Assessment – Italy Hemostatic Agents Market
6.5.5. Brand Assessment: Most Popular Hemostatic Brands - Italy
6.5.6. Winning Imperatives - Decision Making Criteria - Italy
6.5.7. Strategic Developments (Hemostatic Agents) – Italy
6.5.8. Criss-cross Assessment – Product vs. Specialty –Italy
6.5.9. Market Drivers, Restraints, Opportunities, and Trends – Italy
6.5.10. Decision-making Process- Italy
6.5.10.1. Purchase Decision-making Process - Italy
6.5.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - Italy
6.5.10.3. Selection Criteria for Distributors - Italy
6.5.11. Sales Channel Assessment – Italy Hemostatic Agents Market
6.5.12. Customer Landscape
6.5.12.1. Concentration of Hospitals in Italy – Heat Map & Detailed Hospital Segmentation, by Bed Size
6.5.12.2. Key Users of Products, by Specialty/Therapeutic Area – Italy
7. Asia Pacific Hemostatic Agents Market
7.1. China Hemostatic Agents Market
7.1.1. China Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
7.1.1.1. Active Agents
7.1.1.2 Passive Agents
7.1.1.3 Combination
7.1.2. China Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
7.1.2.1. Cardiology
7.1.2.2. Cath Lab
7.1.2.3. Trauma
7.1.2.4. General Surgery
7.1.2.5. ObGyn
7.1.2.7. Transplant
7.1.2.7. Oncology
7.1.2.8. Neurology
7.1.2.9. Orthopedic
7.1.2.10. Plastic Surgery
7.1.2.11. Dental
7.1.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
7.1.3. China Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
7.1.3.1. Large Hospitals (500+ bed size)
7.1.3.2. Medium Hospital (250-499 beds)
7.1.3.3. Small Hospitals (less than 250 beds)
7.1.4. Competition Landscape Assessment – China Hemostatic Agents Market
7.1.5. Brand Assessment: Most Popular Hemostatic Brands-China
7.1.6. Winning Imperatives - Decision Making Criteria - China
7.1.7. Strategic Developments (Hemostatic Agents) – China
7.1.8. Criss-cross Assessment – Product vs. Specialty –China
7.1.9. Market Drivers, Restraints, Opportunities, and Trends – China
7.1.10. Decision-making Process - China
7.1.10.1. Purchase Decision-making Process - China
7.1.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area- China
7.1.10.3. Selection Criteria for Distributors - China
7.1.11. Sales Channel Assessment – China Hemostatic Agents Market
7.1.12. Customer Landscape
7.1.12.1. Concentration of Hospitals in China – Heat Map & Detailed Hospital Segmentation, by Bed Size
7.1.12.2. Key Users of Products, by Specialty/Therapeutic Area – China
7.2. India Hemostatic Agents Market
7.2.1. India Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
7.2.1.1. Active Agents
7.2.1.2 Passive Agents
7.2.1.3 Combination
7.2.2. India Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
7.2.2.1. Cardiology
7.2.2.2. Cath Lab
7.2.2.3. Trauma
7.2.2.4. General Surgery
7.2.2.5. ObGyn
7.2.2.6. Transplant
7.2.2.7. Oncology
7.2.2.8. Neurology
7.2.2.9. Orthopedic
7.2.2.10. Plastic Surgery
7.2.2.11. Dental
7.2.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
7.2.3. India Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
7.2.3.1. Large Hospitals (500+ bed size)
7.2.3.2. Medium Hospital (250-499 beds)
7.2.3.3. Small Hospitals (less than 250 beds)
7.2.4. Competition Landscape Assessment – India Hemostatic Agents Market
7.2.5. Brand Assessment: Most Popular Hemostatic Brands - India
7.2.6. Winning Imperatives - Decision Making Criteria - India
7.2.7. Strategic Developments (Hemostatic Agents) – India
7.2.8. Criss-cross Assessment – Product vs. Specialty –India
7.2.9. Market Drivers, Restraints, Opportunities, and Trends – India
7.2.10. Decision-making Process - India
7.2.10.1. Purchase Decision-making Process - India
7.2.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - India
7.2.10.3. Selection Criteria for Distributors - India
7.2.11. Sales Channel Assessment – India Hemostatic Agents Market
7.2.12. Customer Landscape
7.2.12.1. Concentration of Hospitals in India – Heat Map & Detailed Hospital Segmentation, by Bed Size
7.2.12.2. Key Users of Products, by Specialty/Therapeutic Area – India
7.3. Australia Hemostatic Agents Market
7.3.1. Australia Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
7.3.1.1. Active Agents
7.3.1.2. Passive Agents
7.3.1.3 Combination
7.3.2. Australia Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
7.3.2.1. Cardiology
7.3.2.2. Cath Lab
7.3.2.3. Trauma
7.3.2.4. General Surgery
7.3.2.5. ObGyn
7.3.2.6. Transplant
7.3.2.7. Oncology
7.3.2.8. Neurology
7.3.2.9. Orthopedic
7.3.2.10. Plastic Surgery
7.3.2.11. Dental
7.3.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
7.3.3. Australia Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
7.3.3.1. Large Hospitals (500+ bed size)
7.3.3.2. Medium Hospital (250-399 beds)
7.3.3.3. Small Hospitals (less than 250 beds)
7.3.4. Competition Landscape Assessment – Australia Hemostatic Agents Market
7.3.5. Brand Assessment: Most Popular Hemostatic Brands - Australia
7.3.6. Winning Imperatives - Decision Making Criteria - Australia
7.3.7. Strategic Developments (Hemostatic Agents) – Australia
7.3.8. Criss-cross Assessment – Product vs. Specialty – Australia
7.3.9. Market Drivers, Restraints, Opportunities, and Trends – Australia
7.3.10. Decision-making Process - Australia
7.3.10.1. Purchase Decision-making Process - Australia
7.3.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - Australia
7.3.10.3. Selection Criteria for Distributors - Australia
7.3.11. Sales Channel Assessment – Australia Hemostatic Agents Market
7.3.12. Customer Landscape
7.3.12.1. Concentration of Hospitals in Australia – Heat Map & Detailed Hospital Segmentation, by Bed Size
7.3.12.2. Key Users of Products, by Specialty/Therapeutic Area – Australia
7.4. Japan Hemostatic Agents Market
7.4.1. Japan Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
7.4.1.1. Active Agents
7.4.1.2. Passive Agents
7.4.1.3 Combination
7.4.2. Japan Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
7.4.2.1. Cardiology
7.4.2.2. Cath Lab
7.4.2.3. Trauma
7.4.2.4. General Surgery
7.4.2.5. ObGyn
7.4.2.6. Transplant
7.4.2.7. Oncology
7.4.2.8. Neurology
7.4.2.9. Orthopedic
7.4.2.10. Plastic Surgery
7.4.2.11. Dental
7.4.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
7.4.3. Japan Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
7.4.3.1. Large Hospitals (500+ bed size)
7.4.3.2. Medium Hospital (250-499 beds)
7.4.3.3. Small Hospitals (less than 250 beds)
7.4.4. Competition Landscape Assessment – Japan Hemostatic Agents Market
7.4.5. Brand Assessment: Most Popular Hemostatic Brands - Japan
7.4.6. Winning Imperatives - Decision Making Criteria - Japan
7.4.7. Strategic Developments (Hemostatic Agents) – Japan
7.4.8. Criss-cross Assessment – Product vs. Specialty – Japan
7.4.9. Market Drivers, Restraints, Opportunities, and Trends – Australia
7.4.10. Decision-making Process - Japan
7.4.10.1. Purchase Decision-making Process - Japan
7.4.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - Japan
7.4.10.3. Selection Criteria for Distributors - Japan
7.4.11. Sales Channel Assessment – Japan Hemostatic Agents Market
7.4.12. Customer Landscape
7.4.12.1. Concentration of Hospitals in Japan – Heat Map & Detailed Hospital Segmentation, by Bed Size
7.4.12.2. Key Users of Products, by Specialty/Therapeutic Area – Japan
7.5. South Korea Hemostatic Agents Market
7.5.1. South Korea Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
7.5.1.1. Active Agents
7.5.1.2 Passive Agents
7.5.1.3 Combination
7.5.2. South Korea Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
7.5.2.1. Cardiology
7.5.2.2. Cath Lab
7.5.2.3. Trauma
7.5.2.4. General Surgery
7.5.2.5. ObGyn
7.5.2.7. Transplant
7.5.2.7. Oncology
7.5.2.8. Neurology
7.5.2.9. Orthopedic
7.5.2.10. Plastic Surgery
7.5.2.11. Dental
7.5.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
7.5.3. South Korea Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
7.5.3.1. Large Hospitals (500+ bed size)
7.5.3.2. Medium Hospital (250-499 beds)
7.5.3.3. Small Hospitals (less than 250 beds)
7.5.4. Competition Landscape Assessment – South Korea Hemostatic Agents Market
7.5.5. Brand Assessment: Most Popular Hemostatic Brands - Italy
7.5.6. Winning Imperatives - Decision Making Criteria - Italy
7.5.7. Strategic Developments (Hemostatic Agents) – South Korea
7.5.8. Criss-cross Assessment – Product vs. Specialty – South Korea
7.5.9. Market Drivers, Restraints, Opportunities, and Trends – South Korea
7.5.10. Decision-making Process - South Korea
7.5.10.1. Purchase Decision-making Process - South Korea
7.5.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - South Korea
7.5.10.3. Selection Criteria for Distributors- South Korea
7.5.11. Sales Channel Assessment – South Korea Hemostatic Agents Market
7.5.12. Customer Landscape
7.5.12.1. Concentration of Hospitals in South Korea – Heat Map & Detailed Hospital Segmentation, by Bed Size
7.5.12.2. Key Users of Products, by Specialty/Therapeutic Area – South Korea
8. South Africa Hemostatic Agents Market
8.1. South Africa Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
8.1.1. Active Agents
8.1.2. Passive Agents
8.1.3. Combination
8.2. South Africa Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
8.2.1. Cardiology
8.2.2. Cath Lab
8.2.3. Trauma
8.2.4. General Surgery
8.2.5. ObGyn
8.2.6. Transplant
8.2.8. Oncology
8.2.8. Neurology
8.2.9. Orthopedic
8.2.10. Plastic Surgery
8.2.11. Dental
8.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
8.3. South Africa Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
8.3.1. Large Hospitals (500+ bed size)
8.3.2. Medium Hospital (250-499 beds)
8.3.3. Small Hospitals (less than 250 beds)
8.4. Competition Landscape Assessment – South Africa Hemostatic Agents Market
8.5. Brand Assessment: Most Popular Hemostatic Brands - South Africa
8.6. Winning Imperatives - Decision Making Criteria - South Africa
8.7. Strategic Developments (Hemostatic Agents) – South Africa
8.8. Criss-cross Assessment – Product vs. Specialty – South Africa
8.9. Market Drivers, Restraints, Opportunities, and Trends – South Africa
8.10. Decision-making Process - South Africa
8.10.1. Purchase Decision-making Process - South Africa
8.10.2. Selection Criteria for Products, by Specialty / Therapeutic Area - South Africa
8.10.3. Selection Criteria for Distributors - South Africa
8.11. Sales Channel Assessment – South Africa Hemostatic Agents Market
8.12. Customer Landscape
8.12.1. Concentration of Hospitals in South Africa – Heat Map & Detailed Hospital Segmentation, by Bed Size
8.12.2. Key Users of Products, by Specialty/Therapeutic Area – South Africa
9. Rest of the World (RoW) Hemostatic Agents Market
9.1. Rest of the World (RoW) Hemostatic Agents Market Value Forecast, by Product Type, 2015–2022
9.1.1. Active Agents
9.1.2 Passive Agents
9.1.3 Combination
9.2. Rest of the World (RoW) Hemostatic Agents Market Value Forecast, by Specialty / Therapeutic Area, 2015–2022
9.2.1. Cardiology
9.2.2. Cath Lab
9.2.3. Trauma
9.2.4. General Surgery
9.2.5. ObGyn
9.2.6. Transplant
9.2.7. Oncology
9.2.8. Neurology
9.2.9. Orthopedic
9.2.10. Plastic Surgery
9.2.11. Dental
9.2.12. Others (Urological Surgeries, Pulmonary Surgeries)
9.3. Rest of the World (RoW) Hemostatic Agents Market Value Forecast, by Size of Hospitals, 2015–2022
9.3.1. Large Hospitals (500+ bed size)
9.3.2. Medium Hospital (250-499 beds)
9.3.3. Small Hospitals (less than 250 beds)
10. Company Profiles
10.1. Baxter
10.2. Ethicon US, LLC.
10.3. C. R. Bard, Inc.
10.4. B. Braun Melsungen AG
10.5. Pfizer Inc.
10.6. Z-Medica, LLC.
10.7. CryoLife, Inc.
10.8. Integra LifeSciences
10.9. Advanced Medical Solutions Group plc
10.10. GELITA AG
List of Tables
Table 01: Hemostatic Agents Market Value (US$ Mn), by Regions, 2015–2022
Table 02: Pricing Analysis - U.S.
Table 03: Pricing Analysis - Canada
Table 04: Pricing Analysis - Germany
Table 05: Pricing Analysis - France
Table 06: Pricing Analysis - U.K.
Table 07: Pricing Analysis - Spain
Table 08: Pricing Analysis - Italy
Table 09: Pricing Analysis - China
Table 10: Pricing Analysis - India
Table 11: Pricing Analysis - Australia
Table 12: Pricing Analysis - Japan
Table 13: Pricing Analysis - South Korea
Table 14: Pricing Analysis - South Africa
Table 15: Comparative Assessment of Key Products
Table 16: U.S. Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 17: U.S. Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 18: Brand Assessment: Most Popular Hemostatic Brands - U.S.
Table 19: Criss-cross Assessment – Product vs. Specialty – U.S.
Table 20: Selection Criteria for Products, by Specialty / Therapeutic Area - U.S.
Table 21: U.S. Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 22: Concentration of Hospitals in U.S., by State
Table 23: Detailed Hospital Segmentation in U.S., by Bed Size
Table 24: Canada Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 25: Canada Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 26: Brand Assessment: Most Popular Hemostatic Brands - Canada
Table 27: Criss-cross Assessment – Product vs. Specialty – Canada
Table 28: Selection Criteria for Products, by Specialty / Therapeutic Area - Canada
Table 29: Canada Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 30: Concentration of Hospitals in Canada, by State
Table 31: Detailed Hospital Segmentation in Canada, by Bed Size
Table 32: Germany Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 33: Germany Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 34: Brand Assessment: Most Popular Hemostatic Brands - Germany
Table 35: Criss-cross Assessment – Product vs. Specialty – Germany
Table 36: Selection Criteria for Products, by Specialty / Therapeutic Area - Germany
Table 37: Germany Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 38: Concentration of Hospitals in Germany, by State
Table 39: Detailed Hospital Segmentation in Germany, by Bed Size
Table 40: France Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 41: France Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 42: Brand Assessment: Most Popular Hemostatic Brands - France
Table 43: Criss-cross Assessment – Product vs. Specialty – France
Table 44: Selection Criteria for Products, by Specialty / Therapeutic Area - France
Table 45: France Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 46: Concentration of Hospitals in France, by State
Table 47: Detailed Hospital Segmentation in France, by Bed Size
Table 48: U.K. Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 49: U.K. Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 50: Brand Assessment: Most Popular Hemostatic Brands - U.K.
Table 51: Criss-cross Assessment – Product vs. Specialty – U.K.
Table 52: Selection Criteria for Products, by Specialty / Therapeutic Area - U.K.
Table 53: U.K. Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 54: Concentration of Hospitals in U.K., by State
Table 55: Detailed Hospital Segmentation in U.K., by Bed Size
Table 56: Spain Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 57: Spain Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 58: Brand Assessment: Most Popular Hemostatic Brands - Spain
Table 59: Criss-cross Assessment – Product vs. Specialty – Spain
Table 60: Selection Criteria for Products, by Specialty / Therapeutic Area - Spain
Table 61: Spain Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 62: Concentration of Hospitals in Spain, by State
Table 63: Detailed Hospital Segmentation in Spain, by Bed Size
Table 64: Italy Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 65: Italy Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 66: Brand Assessment: Most Popular Hemostatic Brands - Italy
Table 67: Criss-cross Assessment – Product vs. Specialty – Italy
Table 68: Selection Criteria for Products, by Specialty / Therapeutic Area - Italy
Table 69: Italy Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 70: Concentration of Hospitals in Italy, by State
Table 71: Detailed Hospital Segmentation in Italy, by Bed Size
Table 72: China Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 73: China Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 74: Brand Assessment: Most Popular Hemostatic Brands - China
Table 75: Criss-cross Assessment – Product vs. Specialty – China
Table 76: Selection Criteria for Products, by Specialty / Therapeutic Area - China
Table 77: China Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 78: Concentration of Hospitals in China, by State
Table 79: Detailed Hospital Segmentation in China, by Bed Size
Table 80: India Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 81: India Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 82: Brand Assessment: Most Popular Hemostatic Brands - India
Table 83: Criss-cross Assessment – Product vs. Specialty – India
Table 84: Selection Criteria for Products, by Specialty / Therapeutic Area - India
Table 85: India Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 86: Concentration of Hospitals in India, by State
Table 87: Detailed Hospital Segmentation in India, by Bed Size
Table 88: Australia Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 89: Australia Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 90: Brand Assessment: Most Popular Hemostatic Brands - Australia
Table 91: Criss-cross Assessment – Product vs. Specialty – Australia
Table 92: Selection Criteria for Products, by Specialty / Therapeutic Area - Australia
Table 93: Australia Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 94: Concentration of Hospitals in Australia, by State
Table 95: Detailed Hospital Segmentation in Australia, by Bed Size
Table 96: Japan Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 97: Japan Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 98: Brand Assessment: Most Popular Hemostatic Brands - Japan
Table 99: Criss-cross Assessment – Product vs. Specialty – Japan
Table 100: Selection Criteria for Products, by Specialty / Therapeutic Area - Japan
Table 101: Japan Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 102: Concentration of Hospitals in Japan, by State
Table 103: Detailed Hospital Segmentation in Japan, by Bed Size
Table 104: South Korea Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 105: South Korea Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 106: Brand Assessment: Most Popular Hemostatic Brands - South Korea
Table 107: Criss-cross Assessment – Product vs. Specialty – South Korea
Table 108: Selection Criteria for Products, by Specialty / Therapeutic Area - South Korea
Table 109: South Korea Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 110: Concentration of Hospitals in South Korea, by State
Table 111: Detailed Hospital Segmentation in South Korea, by Bed Size
Table 112: South Africa Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 113: South Africa Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 114: Brand Assessment: Most Popular Hemostatic Brands - South Africa
Table 115: Criss-cross Assessment – Product vs. Specialty – South Africa
Table 116: Selection Criteria for Products, by Specialty / Therapeutic Area - South Africa
Table 117: South Africa Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
Table 118: Concentration of Hospitals in South Africa, by State
Table 119: Detailed Hospital Segmentation in South Africa, by Bed Size
Table 120: Rest of the World (RoW) Hemostatic Agents Market Value (US$ Mn), by Product, 2015–2022
Table 121: Rest of the World (RoW) Hemostatic Agents Market Value (US$ Mn), by Specialty, 2015–2022
Table 122: Rest of the World (RoW) Hemostatic Agents Market Forecast, by Size of Hospital, 2015–2022
List of Figures
Figure 01: Hemostatic Agents Market Value (US$ Mn), 2015–2022
Figure 02: Global Hemostatic Agents Market Share Analysis (2017)
Figure 03: Selection Criteria for Distributors- U.S.
Figure 04: Selection Criteria for Distributors - Canada
Figure 05: Selection Criteria for Distributors - Germany
Figure 06: Selection Criteria for Distributors - France
Figure 07: Selection Criteria for Distributors - U.K.
Figure 08: Selection Criteria for Distributors - Spain
Figure 09: Selection Criteria for Distributors - Italy
Figure 10: Selection Criteria for Distributors - China
Figure 11: Selection Criteria for Distributors - India
Figure 12: Selection Criteria for Distributors - Australia
Figure 13: Selection Criteria for Distributors - Japan
Figure 14: Selection Criteria for Distributors - South Korea
Figure 15: Selection Criteria for Distributors - South Africa
Figure 16: Johnson & Johnson Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 17: Johnson & Johnson R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 18: Johnson & Johnson Breakup of Net Sales, by Region, 2017
Figure 19: Johnson & Johnson Breakup of Net Sales (%), by Business Segment, 2017
Figure 20: Baxter Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 21: Baxter R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 22: Baxter Breakup of Net Sales, by Region, 2017
Figure 23: Baxter Breakup of Net Sales (%), by Business Segment, 2017
Figure 24: Pfizer, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
Figure 25: Pfizer, Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2015–2017
Figure 26: Pfizer, Inc. Breakup of Net Sales, by Business Segment, 2017
Figure 27: Pfizer, Inc. Breakup of Net Sales (%), by Region, 2017
Figure 28: CryoLife, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 29: CryoLife, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 30: CryoLife, Inc. Breakup of Net Sales, by Region, 2017
Figure 31: CryoLife, Inc. Breakup of Net Sales (%), by Business Segment, 2017
Figure 32: C. R. Bard, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 33: C. R. Bard, Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2016
Figure 34: C. R. Bard, Inc. Breakdown of Net Sales, by Region, 2016
Figure 35: C. R. Bard, Inc. Breakdown of Net Sales (%), by Business Segment, 2016
Figure 36: CSL Behring Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 37: CSL Behring R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 38: CSL Behring Net Profit, Y-o-Y, 2014-2017
Figure 39: CSL Behring Breakdown of Net Sales (%), by Business Segment, 2017
Figure 40: B. Braun Melsungen AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 41: B. Braun Melsungen AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
Figure 42: B. Braun Melsungen AG Breakdown of Net Sales (%), by Region, 2017
Figure 43: B. Braun Melsungen AG Breakdown of Net Sales (%), by Business Segment, 2017
Figure 44: Takeda Pharmaceutical Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018
Figure 45: Takeda Pharmaceutical R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2016-2018
Figure 46: Takeda Pharmaceutical Sales, by Region, 2017
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
*86 figures and 60 tables includes